Navigation Links
WaferGen Announces Signing of Private Financing
Date:4/14/2009

rt on Form 10-K for the year ended December 31, 2008. Investors and security holders are urged to read this document free of charge on the SEC's web site at www.sec.gov. The company does not undertake to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

    Contact:

    Vida Communication (Media)                The Trout Group (Investors)
    On Behalf of WaferGen                     On Behalf of WaferGen
    Tim Brons                                 Peter Rahmer
    415-675-7400                              646-378-2973
    tbrons@vidacommunication.com              San Francisco, CA

                                              or

                                              Christine Yang
                                              646-378-2929
                                              New York, NY


'/>"/>
SOURCE WaferGen Biosystems, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. WaferGen Biosystems, ImmuneRegen BioSciences and University of Texas Southwestern Medical Center to Collaborate on Novel Wound Healing Research
2. WaferGen to Present Data on SmartChip(TM) Real-Time PCR System at Cambridge Healthtech Institutes Quantitative PCR Conference
3. Data on WaferGens SmartChip(TM) System Presented at 16th International Molecular Medicine Tri-Conference
4. Data on WaferGens SmartChip Real-Time PCR System(TM) to be Presented at 16th International Molecular Medicine Tri-Conference
5. WaferGens SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program
6. WaferGen Announces Third Quarter 2008 Financial Results
7. WaferGen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
8. NIH Awards Approximately $3M Grant for Research Involving WaferGens SmartChip(TM) Real-Time PCR System at the University of Pittsburgh
9. WaferGen to Present at the Seventh Annual BIO Investor Forum
10. WaferGen Announces Second Quarter 2008 Financial Results
11. WaferGen to Present at the Ninth Annual Beyond Genome Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Clinverse, Inc. , a global ... announced today it has formed a strategic alliance ... FLS eClinical commerce platform aggregates data collected through ... ™, Aggregate Spend Solutions’ recently-launched flagship product, is ... transfer of value at investigator meetings or any ...
(Date:5/21/2013)... 21, 2013 As the R&D ... push within the industry to deliver better products, ... and pharma companies often means turning big ideas ... developed in collaboration with Sensidose AB and Recipharm, ... bring products to market sooner. The partnership resulted ...
(Date:5/21/2013)... , May 21, 2013  MacroGenics, Inc. ... study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal ... expressing the HER2 oncoprotein," will be presented at ... of Clinical Oncology during the Developmental Therapeutics - ... at 4:15 – 4:30 PM.  The presentation will ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Bed bugs have ... to My Cleaning Products, many turn to chemical-based pesticides for ... the health and environmental risks those solutions present, the company ... Bed Bug Bully instead. , According to My Cleaning ... as they used to be. It shared that the pests ...
Breaking Biology Technology:Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 2New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 3
... - Probing the last genomic frontier of higher organisms, an ... understood - but critical - genetic domain in rice. , ... professor of horticulture at the University of Wisconsin-Madison , ... Research in Rockville, Md., has exposed a supposedly barren ...
... Wis. - Chippewa Valley Technical College (CVTC) ... that CVTC will begin teaching nanotechnology as early as ... sweeping changes and opportunities. , ,Jack Uldrich, nanotechnology author, ... described a shift of historic proportions brought on by ...
... , a Wisconsin-based developer of e-Catalog business solutions ... distribution networks, announced it has expanded its software ... , a manufacturer of products for the lawn ... Cub Cadet, Troy-Bilt, Yard-Man, Ryobi, Yard Machines, McCulloch ...
Cached Biology Technology:Rice Centromere, Supposedly Quiet Genetic Domain, Surprises 2Rice Centromere, Supposedly Quiet Genetic Domain, Surprises 3Chippewa Valley Embraces Nanotechnology 2ARI Links e-Catalog Deal with Outdoor Power Equipment Manufacturer 2
(Date:5/20/2013)... are also commonly resistant to antimicrobial substances made ... in mBio , the online open-access journal ... colistin and host antimicrobials LL-37 and lysozyme, which ... mean that patients with life-threatening multi-drug resistant infections ... Colistin is a last-line drug for treating several ...
(Date:5/20/2013)... ITHACA, N.Y. Little is known about the effect ... new study from Cornell University finds that increasing the ... class reduces the probability of obesity. , The study ... effect of PE on youth obesity, and is forthcoming ... An early, online version of the study can be ...
(Date:5/20/2013)... COLUMBUS, Ohio New research suggests that a compound ... "superpower" to escape death. , By altering a ... re-educates cancer cells into normal cells that die as ... by inhibiting a process that would cause them to ... strict programming. This study in cells, led by Ohio ...
Breaking Biology News(10 mins):Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3Gym class reduces probability of obesity, study finds for first time 2The compound in the Mediterranean diet that makes cancer cells 'mortal' 2The compound in the Mediterranean diet that makes cancer cells 'mortal' 3
... The Food and Drug Administration (FDA) today issued a ... and patient caregivers to new safety information concerning an ... antipsychotic drugs." These drugs are approved for the treatment ... drugs to treat behavioral disorders in elderly patients with ...
... mammalian behavior, physiology, and biochemistry are controlled by the ... suprachiasmatic nucleus (SCN). The clock is synchronized to environmental ... from everyday experience, that adjusting to new light schedules ... adaptation takes place are not well understood. Researchers now ...
... results from a large, randomized clinical trial for ... cancer ?cancer that has spread from the breast ... those patients who received bevacizumab (Avastin? in combination ... before their cancer progressed than patients who received ...
Cached Biology News:FDA Warns About Antipsychotic Drugs and Elderly 2After a time-shift, mixed signals from the circadian clock 2Bevacizumab Combined With Chemotherapy Improves Progression-Free Survival for Patients With Advanced Breast Cancer 2Bevacizumab Combined With Chemotherapy Improves Progression-Free Survival for Patients With Advanced Breast Cancer 3
IMAGEQUANT 300 WKSTN, 1 EA. Category: ImageQuant CCD Imagers....
ANTI MYCOBACTERIUM TUBERCULOSIS...
IMAGEQUANT 100 WKSTN, 1 EA. Category: ImageQuant CCD Imagers....
IMAGEQUANT 300 IQTL, 1 EA. Category: ImageQuant CCD Imagers....
Biology Products: